Gout Disease Treatment Market Size, Share, and Growth Forecast 2026 - 2033

The global gout disease treatment market is expected to be valued at US$ 2.8 billion in 2026 and is projected to reach US$ 4.3 billion by 2033, growing at a CAGR of 6.3% between 2026 and 2033. The market is expanding steadily because gout is becoming one of the rapidly growing chronic inflammatory conditions worldwide, while treatment rates remain far below clinical need.

The Global Burden of Disease (GBD) 2021 study, published in The Lancet Rheumatology in 2024, estimated about 55.8 million people were living with gout in 2020, a figure projected to rise to nearly 95.8 million by 2050. Rising obesity, chronic kidney disease, and population ageing are enlarging the patient pool, and treat-to-target guidelines from the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) are encouraging long-term urate-lowering therapy.

Drivers - Rising Prevalence of Gout and Hyperuricemia Linked to Lifestyle and Ageing

The growing global burden of gout and hyperuricemia is the primary factor driving treatment demand. According to the GBD 2021 analysis, the age-standardized prevalence of gout increased by more than 22% between 1990 and 2020, with men affected roughly three times more often than women. Research based on the National Health and Nutrition Examination Survey (NHANES) and published in Arthritis & Rheumatology found that about 9.2 million adults, or 3.9% of the adult population, in the U.S. have gout, while around 20% of adults have hyperuricemia.

Key risk factors are rising sharply, as the World Health Organization (WHO) reports that more than one billion people worldwide were living with obesity in 2022. The United Nations also projects that the population aged 65 and above is expected to reach 1.6 billion by 2050, expanding the high-risk patient base and supporting sustained prescription volumes for acute and chronic gout therapies.

Treat-to-Target Guidelines and Growing Use of Urate-Lowering Therapy

Evolving clinical guidelines are encouraging earlier and more sustained pharmacological treatment of gout. The 2020 ACR Guideline for the Management of Gout strongly recommends a treat-to-target approach that lowers serum urate below 6 mg/dL, and it endorses allopurinol as the preferred first-line urate-lowering agent for most patients, including those with moderate-to-severe chronic kidney disease. Similarly, the EULAR recommendations and the National Institute for Health and Care Excellence (NICE) guideline NG219, published in 2022, advise offering urate-lowering therapy to people with recurrent flares, tophi, or chronic gouty arthritis.

These guidelines also recommend anti-inflammatory prophylaxis with colchicine, NSAIDs, or low-dose corticosteroids for at least three to six months after starting urate-lowering therapy. As a result, each newly diagnosed patient increasingly generates long-term demand across multiple drug classes, strengthening recurring revenue for manufacturers and supporting overall market growth.

Restraints - Safety Concerns Associated with Key Gout Medications

Safety concerns surrounding widely used gout drugs continue to limit prescribing confidence. In February 2019, the U.S. Food and Drug Administration (FDA) added a boxed warning to febuxostat after the CARES trial showed a higher rate of cardiovascular death, at 4.3% compared with 3.2% for allopurinol. Allopurinol itself carries a risk of severe cutaneous adverse reactions, including Stevens-Johnson syndrome, which is strongly associated with the HLA-B 5801 allele, and the ACR recommends genetic screening for patients of Southeast Asian and African American descent.

Long-term NSAID use also raises gastrointestinal, renal, and cardiovascular risks, particularly among older patients with comorbidities. These safety issues narrow treatment options for many patients and slow adoption of certain therapies. They also increase monitoring costs, as patients on these drugs often require regular kidney function tests and cardiovascular risk assessments.

Poor Treatment Adherence and Low Diagnosis Rates

Low treatment adherence and suboptimal disease management significantly restrain market potential. Studies published in the Annals of the Rheumatic Diseases and Rheumatology report that fewer than half of patients with gout receive urate-lowering therapy, and among those who do, adherence rates often fall below 50% within the first year. Many patients view gout as an episodic condition and stop medication once flares subside, while primary care physicians frequently fail to titrate doses to reach target serum urate levels.

Research in the U.K. has shown that only a minority of treated patients achieve the recommended urate target. This treatment gap limits long-term prescription volumes, particularly for premium urate-lowering agents, and results in recurring hospitalizations that shift spending toward acute rather than chronic care.

Opportunities - Emerging Biologics and Novel Therapies for Refractory Gout

The development of advanced biologics and next-generation urate-lowering agents presents a major growth opportunity for pharmaceutical companies. Uncontrolled gout, which does not respond to conventional oral therapy, affects a meaningful subset of patients and is associated with severe tophi and joint damage. KRYSTEXXA (pegloticase), now marketed by Amgen following its acquisition of Horizon Therapeutics, received FDA approval in July 2022 for co-administration with methotrexate after the MIRROR RCT trial showed a sustained response rate of 71% compared with 39% for pegloticase alone.

Strong commercial interest in this space was confirmed when Amgen completed the Horizon acquisition in October 2023 for around US$ 27.8 billion. The pipeline also includes SEL-212, a combination therapy originally developed by Selecta Biosciences and licensed to Sobi, as well as novel URAT1 inhibitors such as epaminurad from JW Pharmaceutical and tigulixostat from LG Chem, which are expected to broaden treatment options significantly.

Expanding Access through Emerging Markets and Digital Pharmacy Channels

Rising disease awareness and improving healthcare access in emerging economies create significant opportunities for both branded and generic manufacturers. Asia Pacific is experiencing a rapid increase in hyperuricemia, with the China Chronic Disease and Risk Factor Surveillance survey reporting a hyperuricemia prevalence of about 14% among Chinese adults in 2018 to 2019. Government insurance programs, including India's Ayushman Bharat and China's National Reimbursement Drug List (NRDL), are improving affordability of chronic disease medications.

At the same time, online pharmacies and telehealth platforms are transforming how patients refill long-term prescriptions, improving adherence through automatic refill reminders and home delivery. Companies that combine affordable generic urate-lowering agents with digital patient support programs, such as serum urate monitoring apps and nurse-led follow-up, are well positioned to capture expanding demand across both developed and emerging markets over the forecast period.

Drug Class Insights

NSAIDs lead the drug class category with around 38% market share in 2026, reflecting their role as widely used first-line treatments for acute gout flares. The ACR and EULAR guidelines recommend NSAIDs, colchicine, or corticosteroids as appropriate first-line options, while NSAIDs such as naproxen, indomethacin, and ibuprofen are often preferred due to their rapid pain relief, broad availability, and low cost. Their accessibility through both prescription and over-the-counter channels further supports high utilization, particularly in primary care and emergency settings where acute flares are commonly treated.

Urate-lowering agents are projected to be the fastest-growing segment through 2033, driven by treat-to-target guidelines, rising diagnosis of chronic gout, and the introduction of novel biologics and URAT1 inhibitors targeting patients with uncontrolled disease. Increasing recognition of the need for sustained serum uric acid reduction is also shifting treatment toward long-term disease management rather than flare control alone. Growing adoption of therapies such as febuxostat, pegloticase, and emerging urate transport inhibitors is expanding treatment options for patients who do not achieve adequate control with conventional therapy.

Route of Administration Insights

The oral segment is expected to dominate the gout disease treatment market, holding around 82% share in 2026, as nearly all standard gout treatments, including allopurinol, febuxostat, colchicine, NSAIDs, and oral corticosteroids, are available in convenient tablet or capsule forms. Oral drugs are inexpensive, easy to self-administer, and suitable for long-term daily use, aligning with the lifelong nature of urate-lowering therapy recommended by the ACR. Allopurinol is among the most commonly prescribed medications in the United States, with millions of prescriptions dispensed each year according to Medical Expenditure Panel Survey (MEPS) data from the Agency for Healthcare Research and Quality (AHRQ).

The injectable segment is expected to register the fastest CAGR through 2033, supported by biologics such as KRYSTEXXA and ILARIS (canakinumab), which target patients with refractory gout or contraindications to oral agents. Growth is further supported by increasing recognition of treatment-resistant gout and demand for therapies that provide targeted disease control when conventional oral medicines are insufficient. Advancements in biologic formulations, infusion-based treatment, and specialty care access are also expanding the addressable patient pool for injectable therapies.

End-User Insights

Retail pharmacies hold the leading position in the gout disease treatment market, capturing a 52% share in 2026, as gout is primarily managed in outpatient and primary care settings where patients fill long-term prescriptions for urate-lowering therapy and medications for acute flares. Retail pharmacy chains offer wide geographic coverage, pharmacist counseling, and convenient refill services, supporting adherence among patients requiring daily medication. In the United States, the National Community Pharmacists Association (NCPA) notes that community pharmacies remain one of the most accessible healthcare touchpoints, particularly in rural areas. Hospital pharmacies retain a significant share due to injectable biologic infusions and the treatment of severe flares.

Online pharmacies are projected to register the fastest CAGR through 2033, driven by telehealth adoption, home delivery, and subscription-based refill models for chronic disease medications. The expansion of digital prescribing and virtual consultations is improving access to gout treatments, particularly for patients requiring recurring prescriptions and long-term urate-lowering therapy. Automated refills, prescription reminders, and direct-to-home delivery are further supporting medication continuity while enabling online platforms to capture a larger share of chronic disease prescription fulfillment.

North America Gout Disease Treatment Market Trends and Insights

North America is expected to dominate the global gout disease treatment market with a 38% share in 2026, supported by high disease prevalence, strong awareness, and favorable access to both generic and branded therapies. The region represents the largest market for biologics such as KRYSTEXXA, and major pharmaceutical companies continue to invest heavily in clinical research for uncontrolled gout. Key regional trends include increasing use of infusion centers for biologic therapy, adoption of treat-to-target protocols in primary care, and growing interest in pharmacist-led gout management programs.

High rates of obesity, type 2 diabetes, hypertension, and chronic kidney disease across the region continue to expand the patient pool, while robust insurance coverage and patient assistance programs support long-term leadership of the region. There is rising telehealth use, helping patients stay on long-term treatment.

U.S. Gout Disease Treatment Market Size

The U.S. gout disease treatment market is estimated at around US$ 950 million in 2026. Growth is supported by about 9.2 million adults living with gout, according to NHANES-based research, and by the CDC reporting that more than 40% of American adults live with obesity, a major gout risk factor. The FDA has approved several advanced therapies, including KRYSTEXXA with methotrexate in 2022 and ILARIS for gout flares in 2023, expanding options for difficult-to-treat patients.

Medicare and commercial insurance coverage, together with manufacturer patient support programs, improve access to premium therapies. Opportunities are growing in refractory gout biologics and in digital care programs that improve adherence to urate-lowering therapy nationwide. Growing investment by specialty pharmacies in infusion services further supports biologic uptake in the U.S.

Europe Gout Disease Treatment Market Trends and Insights

Europe represents the second-largest market, supported by comprehensive public healthcare systems, well-established clinical guidelines, and high generic drug penetration. The EULAR recommendations promote a treat-to-target strategy and patient education as key components of gout care, while the European Medicines Agency (EMA) regulates approvals of new urate-lowering agents across member states. Febuxostat is widely available through brands such as ADENURIC from the Menarini Group, alongside low-cost allopurinol generics.

Key trends in the regional market include nurse-led gout clinics, growing awareness campaigns by patient associations, and increasing attention to cardiovascular safety in prescribing decisions. An ageing population and rising obesity rates across the region are expected to sustain steady demand, although price controls and generic competition moderate revenue growth. Novel URAT1 inhibitors in late-stage development offer immense growth opportunities.

Germany Gout Disease Treatment Market Size

Germany’s gout disease treatment market is expected to be valued at US$ 170 million in 2026. Epidemiological studies have estimated gout prevalence in Germany at about 1.4% of the adult population, making it one of the higher-burden countries in Western Europe. According to the Federal Statistical Office of Germany (Destatis), more than 22% of the population is aged 65 and above, a group at elevated risk of hyperuricemia and gout. Statutory health insurance provides broad coverage for gout medications, and the German Society for Rheumatology (DGRh) promotes guideline-based care.

Strong rheumatology infrastructure and rising use of urate-lowering therapy support continued market growth through 2033. Increasing uptake of febuxostat among patients intolerant to allopurinol and wider access to rheumatology specialists in urban centers also contribute to steady revenue expansion across the country.

U.K. Gout Disease Treatment Market Size

The U.K. gout disease treatment market is projected to reach US$ 120 million in 2026. Research using the Clinical Practice Research Datalink (CPRD) has estimated gout prevalence in the U.K. at around 2.5%, one of the highest rates in Europe. The NICE guideline NG219, published in 2022, recommends offering a treat-to-target urate-lowering therapy strategy to all patients with recurrent flares, which is expected to increase long-term prescribing. Versus Arthritis and the UK Gout Society continue to raise awareness of gout as a chronic disease.

Growing nurse-led care models within the National Health Service (NHS) are also improving adherence and treatment outcomes across the country. Wider use of annual serum urate monitoring in primary care and pharmacist-supported medication reviews is expected to further lift prescription volumes through 2033.

France Gout Disease Treatment Market Size

France’s gout disease treatment market is expected to reach around US$ 105 million in 2026. A national survey published in the Joint Bone Spine journal estimated gout prevalence in France at about 0.9% of adults, with higher rates among older men. The French Society for Rheumatology (SFR) has issued recommendations aligned with a treat-to-target approach, encouraging broader use of allopurinol and febuxostat. Universal coverage under the national health insurance system reduces out-of-pocket costs for patients with chronic conditions.

Rising obesity and metabolic syndrome, along with increasing patient education efforts led by rheumatology networks, are expected to support steady growth in gout treatment demand across the country through 2033. Growing interest in combination regimens for patients with frequent flares and the expanding role of pharmacists in chronic disease follow-up are also contributing to market expansion.

Asia Pacific Gout Disease Treatment Market Trends and Insights

Asia Pacific is projected to register the fastest CAGR between 2026 and 2033, driven by rapid lifestyle changes, rising consumption of purine-rich diets and sugary beverages, and ageing populations. China carries one of the region’s largest disease burdens, with national surveillance data showing hyperuricemia in about 14% of adults, while the National Healthcare Security Administration (NHSA) continues to expand reimbursement for chronic disease drugs through the NRDL. Domestic manufacturers such as Simcere Pharmaceutical Group are strengthening their presence alongside multinational companies.

Across the region, improving diagnosis rates, expanding health insurance coverage, and growing availability of affordable generic urate-lowering agents are accelerating treatment uptake, while countries such as Japan and South Korea remain important centers for novel drug development. Rapid expansion of e-pharmacy platforms is also widening access to long-term therapies, particularly for patients requiring ongoing urate-lowering treatment.

India Gout Disease Treatment Market Size

India’s gout disease treatment market is estimated at around US$ 60 million in 2026. Rising urbanization, sedentary lifestyles, and a high prevalence of metabolic disorders are increasing hyperuricemia cases, with the Indian Council of Medical Research (ICMR)-INDIAB study reporting that more than 100 million Indians have diabetes, a key comorbidity linked to gout. Government health coverage under Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY), covering more than 550 million beneficiaries, and the Jan Aushadhi scheme for affordable generics are improving access to treatment.

Domestic manufacturers such as Zydus Lifesciences supply low-cost febuxostat and allopurinol, supporting treatment volume growth through 2033. Expanding telemedicine services and online pharmacies are further improving access to chronic gout care in smaller cities and rural areas, while greater awareness of long-term urate management is supporting sustained demand for treatment.

The global gout disease treatment market is moderately fragmented, with a mix of multinational pharmaceutical companies, specialty biologics developers, and generic manufacturers competing across drug classes. Leading companies such as Amgen, Takeda Pharmaceutical Company, Novartis, Teijin Pharma, and the Menarini Group differentiate through branded urate-lowering agents, biologics for refractory gout, and strong physician engagement programs. Generic manufacturers, including Zydus Lifesciences, compete aggressively on price in allopurinol, febuxostat, and colchicine.

Mergers and acquisitions remain a core growth strategy, as shown by Amgen's acquisition of Horizon Therapeutics. Research and development efforts focus on selective URAT1 inhibitors, long-acting uricase therapies, and interleukin-1 blockers. Emerging business models include patient support services, infusion center partnerships, and digital adherence programs aimed at improving long-term treatment outcomes.

Key Industry Developments

• In July 2025, Eisai launches URECE (dotinurad) in China for gout treatment. URECE selectively inhibits the URAT1 transporter, reducing uric acid reabsorption in the kidneys. The launch followed China's December 2024 approval of the drug for gout patients with hyperuricemia.
• In October 2025, Atom Therapeutics announced partnering opportunities for its novel gout therapies at BIO-Europe 2025 in Vienna, highlighting its pipeline of treatments for chronic and acute gout. Its lead candidate ABP-671 (lingdolinurad) is a novel oral URAT1 inhibitor for chronic gout and hyperuricemia, while ABP-745 is being developed for acute gout flares.